NASDAQ:LPCN Lipocine (LPCN) Stock Price, News & Analysis → Top Project Outperforms BTC in 2023… (From Crypto 101 Media) (Ad) Free LPCN Stock Alerts $5.24 +0.11 (+2.14%) (As of 02:17 PM ET) Add Compare Share Share Today's Range$4.85▼$5.3050-Day Range$3.58▼$5.2152-Week Range$2.31▼$5.95Volume46,597 shsAverage Volume29,587 shsMarket Capitalization$27.88 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Lipocine alerts: Email Address Lipocine MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish2.40% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.31Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.75) to ($2.06) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.04 out of 5 starsMedical Sector938th out of 938 stocksPharmaceutical Preparations Industry433rd out of 433 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Lipocine. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.40% of the float of Lipocine has been sold short.Short Interest Ratio / Days to CoverLipocine has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Lipocine has recently increased by 11.55%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLipocine does not currently pay a dividend.Dividend GrowthLipocine does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LPCN. Previous Next 3.0 News and Social Media Coverage News SentimentLipocine has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Lipocine this week, compared to 0 articles on an average week.Search Interest3 people have searched for LPCN on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows4 people have added Lipocine to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lipocine insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.00% of the stock of Lipocine is held by insiders.Percentage Held by InstitutionsOnly 9.11% of the stock of Lipocine is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Lipocine are expected to decrease in the coming year, from ($1.75) to ($2.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lipocine is -1.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lipocine is -1.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLipocine has a P/B Ratio of 1.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaTop Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.Just click here for instant access to the #1 Coin for 2024. About Lipocine Stock (NASDAQ:LPCN)Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1154 for postpartum depression; LPCN 2101 for women with epilepsy; and LPCN 1148, a novel prodrug of testosterone, testosterone laurate for the management of decompensated cirrhosis. It also develops LPCN 1144, an oral prodrug of androgen receptor modulator for the treatment of non-cirrhotic non-alcoholic steatohepatitis, which has completed Phase II testing; LPCN 1111, an oral TRT product of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical testing; and LPCN 1107, an oral hydroxy progesterone caproate product for the prevention of recurrent preterm birth. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.Read More LPCN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LPCN Stock News HeadlinesMarch 28, 2024 | markets.businessinsider.comLipocine: LPCN 1148 Meets Primary And Hepatic Encephalopathy Endpoints In Phase 2 StudyMarch 28, 2024 | prnewswire.comLipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with CirrhosisMarch 28, 2024 | Porter & Company (Ad)AI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… March 26, 2024 | americanbankingnews.comLipocine (NASDAQ:LPCN) Stock Crosses Above Fifty Day Moving Average of $3.97March 26, 2024 | americanbankingnews.comLipocine (NASDAQ:LPCN) Now Covered by Analysts at StockNews.comMarch 25, 2024 | finance.yahoo.comCirrhosis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsightMarch 25, 2024 | prnewswire.comLipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154March 18, 2024 | americanbankingnews.comLipocine (NASDAQ:LPCN) Receives New Coverage from Analysts at StockNews.comMarch 28, 2024 | Porter & Company (Ad)AI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… March 7, 2024 | investorplace.comLPCN Stock Earnings: Lipocine Beats EPS for Q4 2023March 7, 2024 | seekingalpha.comLipocine GAAP EPS of -$3.14March 7, 2024 | prnewswire.comLipocine Announces Financial Results for the Full Year Ended December 31, 2023March 6, 2024 | finance.yahoo.comLipocine to Present at 36th Annual Roth ConferenceFebruary 6, 2024 | finance.yahoo.comLipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154February 2, 2024 | finanznachrichten.deLipocine Inc.: Lipocine Announces Continued Commercialization of TLANDO through Verity PharmaceuticalsFebruary 2, 2024 | fr.investing.comLipocine transfère la commercialisation de TLANDO à Verity PharmaFebruary 2, 2024 | finance.yahoo.comLipocine Announces Continued Commercialization of TLANDO® through Verity PharmaceuticalsJanuary 18, 2024 | marketwatch.comLipocine Shares Rise Premarket on Tlando Licensing DealJanuary 18, 2024 | msn.comLipocine licenses Tlando testosterone therapy to Verity PharmaJanuary 18, 2024 | markets.businessinsider.comLipocine Signs TLANDO Franchise License Deal With Verity PharmaJanuary 18, 2024 | finance.yahoo.comLipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and CanadaDecember 19, 2023 | finance.yahoo.comLipocine to Present at Biotech Showcase 2024November 22, 2023 | msn.comLipocine files for $150M mixed shelfNovember 13, 2023 | marketwatch.comLipocine to Share Cirrhosis Treatment LPCN 1148 Results at The Liver MeetingNovember 13, 2023 | finance.yahoo.comLipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023November 10, 2023 | markets.businessinsider.comBuy Rating for Lipocine: Anticipation of Successful LPCN 1154 Study and Strong Financial PositionNovember 8, 2023 | finance.yahoo.comLipocine Announces Financial Results for the Third Quarter Ended September 30, 2023See More Headlines Receive LPCN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lipocine and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today3/28/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LPCN CUSIPN/A CIK1535955 Webwww.lipocine.com Phone(801) 994-7383Fax801-994-7388Employees17Year Founded1997Profitability EPS (Most Recent Fiscal Year)($3.0503) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,350,000.00 Net MarginsN/A Pretax Margin-21,921.82% Return on Equity-63.28% Return on Assets-58.27% Debt Debt-to-Equity RatioN/A Current Ratio8.69 Quick Ratio8.69 Sales & Book Value Annual Sales$500,000.00 Price / Sales55.43 Cash FlowN/A Price / Cash FlowN/A Book Value$3.83 per share Price / Book1.36Miscellaneous Outstanding Shares5,320,000Free Float5,040,000Market Cap$27.72 million OptionableNo Data Beta1.02 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Mahesh V. Patel Ph.D. (Age 67)Co-Founder, Interim Principal Financial Officer, Director, President & CEO Comp: $598.91kMs. Krista Fogarty (Age 56)Principal Accounting Officer & Corporate Controller Comp: $268.12kDr. Nachiappan Chidambaram Ph.D. (Age 54)Senior Vice President of Research & Development Comp: $311.17kMr. Logan Morse (Age 54)Vice President of Sales, Marketing & Operations Comp: $413.58kMr. Morgan R. Brown CPA (Age 56)M.B.A., Corporate Secretary Comp: $472.45kKey CompetitorsLisata TherapeuticsNASDAQ:LSTAOrgenesisNASDAQ:ORGSSensei BiotherapeuticsNASDAQ:SNSESol-Gel TechnologiesNASDAQ:SLGLFSD PharmaNASDAQ:HUGEView All CompetitorsInsiders & InstitutionsWealth Effects LLCSold 4,122 shares on 1/29/2024Ownership: 0.275%Mahesh V PatelBought 8,706 shares on 5/25/2023Total: $43,791.18 ($5.03/share)View All Insider TransactionsView All Institutional Transactions LPCN Stock Analysis - Frequently Asked Questions How have LPCN shares performed in 2024? Lipocine's stock was trading at $2.79 at the start of the year. Since then, LPCN stock has increased by 87.8% and is now trading at $5.24. View the best growth stocks for 2024 here. When is Lipocine's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our LPCN earnings forecast. How were Lipocine's earnings last quarter? Lipocine Inc. (NASDAQ:LPCN) posted its earnings results on Thursday, March, 7th. The specialty pharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.53) by $0.11. The specialty pharmaceutical company had revenue of $0.22 million for the quarter. When did Lipocine's stock split? Shares of Lipocine reverse split on the morning of Friday, May 12th 2023. The 1-17 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. What other stocks do shareholders of Lipocine own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lipocine investors own include Synergy Pharmaceuticals (SGYP), Flexion Therapeutics (FLXN), Trevena (TRVN), Heat Biologics (HTBX), Rigel Pharmaceuticals (RIGL), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Biocept (BIOC) and Catalyst Pharmaceuticals (CPRX). Who are Lipocine's major shareholders? Lipocine's stock is owned by a number of institutional and retail investors. Top institutional investors include Wealth Effects LLC (0.28%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Krista Fogarty, Mahesh V Patel, Richard Dana Ono and Spyros Papapetropoulos. View institutional ownership trends. How do I buy shares of Lipocine? Shares of LPCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LPCN) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeAI to Meet the Same Fate as EVs? Porter & CompanyGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipocine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.